![Root to Rx Issue 012 - The Informed [Web Only]: The Pharma Profit Question](https://media.beehiiv.com/cdn-cgi/image/format=auto,width=720,fit=scale-down,onerror=redirect/uploads/asset/file/3745b979-65df-4060-a88f-ae1eb4129183/3.png)
Cancer
+1
Jun 25, 2026
•
8 min read
Root to Rx Issue 011 - Plain Talk: The 40-Year Bill
Who built the drug. Who can afford it. And the week the doctors turned on the price.
Cancer
+1
![Root to Rx Issue 011 - The Informed [Web Only]: Access and Pricing](https://media.beehiiv.com/cdn-cgi/image/format=auto,width=720,fit=scale-down,onerror=redirect/uploads/asset/file/e5c5a609-c9bd-4248-a6d2-9b2307667f31/3.png)
Jun 25, 2026
•
6 min read
Root to Rx Issue 011 - The Informed [Web Only]: Access and Pricing
What the Gleevec story leaves unfinished, and the year the doctors pushed back.
Cancer
+1
Jun 18, 2026
•
7 min read
Root to Rx Issue 010 - Plain Talk: The 2.5-Month Miracle
FDA review. Accelerated approval. And what regulatory speed actually requires.
Cancer
+1
![Root to Rx Issue 010 - The Informed [Web Only]: Fast Review, Full Standard](https://media.beehiiv.com/cdn-cgi/image/format=auto,width=720,fit=scale-down,onerror=redirect/uploads/asset/file/2e20eea5-78ab-4f3a-9a59-2f7c8c600535/The_Informed.png)
Jun 18, 2026
•
8 min read
Root to Rx Issue 010 - The Informed [Web Only]: Fast Review, Full Standard
What the 72-day Gleevec review required, and the real difference between priority review, accelerated approval, and breakthrough designation.
![Root to Rx Issue 010 - The Root Room [Web Only]: The Weight of the Record](https://media.beehiiv.com/cdn-cgi/image/format=auto,width=720,fit=scale-down,onerror=redirect/uploads/asset/file/dbbaa4bd-c3b2-422e-bc86-6b06ef0727c5/The_Root_Room.png)
Cancer
+1
Jun 11, 2026
•
6 min read
Root to Rx Issue 009 - Plain Talk: Scale
How 1,106 patients across 16 countries built the case for a drug that changed cancer treatment.
Cancer
+1
![Root to Rx Issue 009 - The Informed [Web Only]: Phase II, Phase III, and the Trial That Changed Oncology](https://media.beehiiv.com/cdn-cgi/image/format=auto,width=720,fit=scale-down,onerror=redirect/uploads/asset/file/3338ed49-60a5-4379-bc4e-d891025a59b3/NL_NLinline_Ph3Tracks.png)
Jun 11, 2026
•
6 min read
Root to Rx Issue 009 - The Informed [Web Only]: Phase II, Phase III, and the Trial That Changed Oncology
How the IRIS trial was designed, why it stopped early, and what the COVID vaccine timeline actually means.
![Root to Rx Issue 009 - The Root Room [Web Only]: The First Day](https://media.beehiiv.com/cdn-cgi/image/format=auto,width=720,fit=scale-down,onerror=redirect/uploads/asset/file/7c7d6aa4-98ac-4d84-83e4-186cd1b26e69/RR-01__Hero___Full_Width.jpg)
Cancer
+1
Jun 4, 2026
•
7 min read
Root to Rx Issue 008 - Plain Talk: A Game of Life
What happens when a drug stops working, and why that is not the end of this story
Cancer
+1
![Root to Rx Issue 008 - The Informed [Web Only]: Resistance Is Not the End](https://media.beehiiv.com/cdn-cgi/image/format=auto,width=720,fit=scale-down,onerror=redirect/uploads/asset/file/cf6bef39-7142-4630-81a3-27924a2de3ad/Untitled_design.png)
Jun 4, 2026
•
6 min read
Root to Rx Issue 008 - The Informed [Web Only]: Resistance Is Not the End
The science of what comes after a drug stops working.
![Root to Rx Issue 008 - The Root Room [Web Only]: Debby Learns to Listen First in the Waiting Room](https://media.beehiiv.com/cdn-cgi/image/format=auto,width=720,fit=scale-down,onerror=redirect/uploads/asset/file/2f27e0bc-adb6-4a76-a5d7-62028cceecfd/PAUSE_Card_newsletter.png)
Cancer
+1
May 28, 2026
•
8 min read
Root to Rx Issue 007 - Plain Talk: The Trial That Stopped Itself
The FDA approved Gleevec in 71 days. Here is what that actually means.
